Australia markets closed

Zealand Pharma A/S (0NZU.IL)

IOB - IOB Delayed price. Currency in DKK
Add to watchlist
763.50-35.75 (-4.47%)
At close: 05:33PM BST
Full screen
Previous close799.25
Open786.50
Bid744.50 x 0
Ask782.50 x 0
Day's range752.50 - 788.50
52-week range276.00 - 969.00
Volume5,651
Avg. volume50,656
Market cap45.523B
Beta (5Y monthly)0.62
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024

    Company announcement – No. 46 / 2024 Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024 Copenhagen, Denmark, September 30, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end

  • GlobeNewswire

    Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th

    Press Release – No. 9 / 2024 Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th Copenhagen, Denmark, September 13, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Medical Officer, David Kendall, MD, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference at 9:10 a.m. ET (3:10 p.m. CET) on Wednesday, Sep

  • GlobeNewswire

    Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

    Company announcement – No. 45 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, September 12, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 10,110 divided into 10,110 new shares with a nominal value of DKK 1 each. The i